Saturday, 23 September 2017
Latest news
Main » Marvell Technology Group Ltd. (MRVL) Given Buy Rating at Oppenheimer Holdings, Inc

Marvell Technology Group Ltd. (MRVL) Given Buy Rating at Oppenheimer Holdings, Inc

04 September 2017

Manhattan Assoc had 11 analyst reports since July 22, 2015 according to SRatingsIntel. Jefferies maintained China Biologic Products Holdings, Inc. The firm now has a $23.00 price target on the semiconductor company's stock. The firm has "Buy" rating given on Monday, July 10 by Susquehanna. Jefferies maintained it with "Hold" rating and $1900 target in Thursday, May 25 report. As per Friday, May 6, the company rating was maintained by Topeka Capital Markets. The rating was downgraded by Morgan Stanley to "Equal-Weight" on Monday, September 14. The firm has "Buy" rating by Canaccord Genuity given on Wednesday, September 16. See Manhattan Associates, Inc.

Marvell Technology Group Ltd. (MRVL) maintained activity of 6.95 million shares that trade hands on average basis while its relative volume is 0.98. This translates into $115.54M profit for MRVL giving the stock a 18.63 P/E. The semiconductor company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.04.

The stock decreased 1.04% or $0.97 during the last trading session, reaching $92.23.

More news: Are Analysts Bullish Workspace Group plc (LON:WKP) After Last Week?

About 10.21 million shares traded or 96.35% up from the average. Also Nasdaq.com published the news titled: "Earnings Reaction History: Marvell Technology Group Ltd., 25.0% Follow-Through ..." on August 24, 2017. It has outperformed by 47.84% the S&P500.The move comes after 6 months positive chart setup for the $8.64B company. Return on Assets (ROA) value of the stock is 0 Percent. It has underperformed by 18.18% the S&P500. The company has market cap of $7.97 billion. It operates through three divisions: Americas, EMEA and APAC. It has a 33.21 P/E ratio. It is engaged in developing, selling, deploying, servicing and maintaining software solutions created to manage supply chains, inventory and omni-channel activities for retailers, wholesalers, manufacturers, logistics providers and other organizations.

Investors sentiment is 0.89 in 2016 Q4. Its up 0.20, from 1.07 in 2016Q3. It is the same, as 34 investors sold UTHR shares while 144 reduced holdings. only 52 funds opened positions while 107 raised stakes.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Axa has invested 0.2% of its portfolio in Cerner Corporation (NASDAQ:CERN). Texas Permanent School Fund invested 0.04% of its portfolio in Manhattan Associates, Inc. 1St Source Fincl Bank reported 20,649 shares stake.

More news: LSU dominates BYU, 27-0

Glenview Capital Management Llc increased Vereit Inc stake by 3.53M shares to 17.92 million valued at $151.59M in 2016Q4. Piedmont Inv Limited Liability invested in 0% or 47,511 shares. Moreover, Bokf Na has 0.15% invested in United Therapeutics Corporation (NASDAQ:UTHR). Weaver C Barksdale & Assoc Inc accumulated 0.01% or 66 shares. Dekabank Deutsche Girozentrale holds 0% or 9,158 shares. Strategic Global Limited has invested 0.64% in United Therapeutics Corporation (NASDAQ:UTHR). Macquarie Group Incorporated reported 14,100 shares. State Of Tennessee Treasury Department owns 993,965 shares for 0.07% of their portfolio. Therefore 45% are positive. MRVL generated revenue of $638.8 Million in the same quarter, one year ago. UBS has "Sell" rating and $12 target. Finally, CIBC raised shares of Marvell Technology Group from a "market perform" rating to an "outperform" rating in a research report on Friday, May 26th. The firm earned "Hold" rating on Thursday, July 27 by Cowen & Co. The rating was maintained by Oppenheimer on Tuesday, June 13 with "Buy". (NASDAQ:CBPO) rating on Monday, June 12.

For the Current Quarter, the growth estimate for Marvell Technology Group Ltd.is 55.6%, while for the Next Quarter the stock growth estimate is 55%. As per Monday, September 14, the company rating was maintained by Cowen & Co.

Investors sentiment decreased to 1.09 in 2016 Q4. Next quarter's EPS is forecasted at $0.27 with next year's EPS anticipated to be $1.23. The stock has advanced 31.84% to a low over the previous 12 months and showed declining move -12.76% to a high over the same period. Sold All: 25 Reduced: 106 Increased: 95 New Position: 71. The hedge funds in our partner's database now own: 354.78 million shares, down from 363.11 million shares in 2016Q3. 35,105 were reported by Massmutual Tru Fsb Adv. Ensemble Capital Management Llc owns 19,980 shares. Oxford Asset Mgmt holds 0.29% or 418,449 shares. Blackrock reported 2.96 million shares. Davis holds 2.03% or 60,255 shares in its portfolio. The Return on Investment (ROI) ratio of Marvell Technology Group Ltd. (MRVL) is 0.7 percent. The stock sank -1.18% last month and is up 14.35 this year.

More news: Who Should Play the Joker? Leonardo DiCaprio, Say Warner Bros

Analysts are also projecting an Average Revenue Estimate for Marvell Technology Group Ltd.as $600700 in the Current Quarter. Goldman Sachs Gru Inc holds 9.55M shares or 0.04% of its portfolio. Panagora Asset Management owns 0.01% invested in Marvell Technology Group Ltd. (NASDAQ:MRVL) for 128,144 shares. James Investment Research Inc. bought a new position in shares of Marvell Technology Group during the first quarter valued at approximately $138,000. Kcm Investment Advsrs Llc holds 4,465 shares or 0.01% of its portfolio.

Marvell Technology Group Ltd. (MRVL) Given Buy Rating at Oppenheimer Holdings, Inc